Clinical trials: NSCLC, Squamous or Non-Squamous
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Non Squamous Non Small Cell Lung Cancer
Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
The objective of this bridging study is to acquire new drug approval in Korea for camrelizumab (SHR-1210), a drug that has already been approved in China for treatment in patients with histologically or cytologically confirmed…
- Trial name
- NCT05841472
- Testing
- Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin
- Where
- 8 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- CrystalGenomics, Inc.
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of oblimersen in treating patients who have solid tumors…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00003103
- Testing
- oblimersen sodium, docetaxel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer…
- Trial name
- NCT06933329
- Testing
- Zelenectide pevedotin
- Where
- 3 sites in France, Spain
- Volunteers
- 73 people
- Sponsor
- BicycleTx Limited
Lung Cancer
Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer
RATIONALE: Surgical removal of all lymph nodes in the chest may kill cancer cells that have spread from tumors in the lung. It is not yet known whether complete removal of all lymph nodes in the chest is more effective than…
- Trial name
- NCT00003831
- Testing
- conventional surgery
- Where
- 74 sites in United States, Australia and 1 more
- Volunteers
- 1,023 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine followed by docetaxel in treating patients…
- Trial name
- NCT00026156
- Testing
- docetaxel, vinorelbine tartrate
- Where
- 96 sites in United States
- Volunteers
- 125 people
- Sponsor
- SWOG Cancer Research Network
Squamous Cell Non-small Cell Lung Cancer
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
The purpose of the study is to compare the overall survival of BMS-936558 as compared with Docetaxel in subjects with squamous cell non-small cell lung cancer (NSCLC), after failure of prior platinum-based chemotherapy.
- Trial name
- NCT01642004
- Testing
- Nivolumab, Docetaxel
- Where
- 127 sites in United States, Argentina and 19 more
- Volunteers
- 272 people
- Sponsor
- Bristol-Myers Squibb
Squamous NSCLC
Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
Efficacy and Safety Evaluation of IBI308 in Patients with Advanced or Recurrent Squamous NSCLC
- Trial name
- NCT03629925
- Testing
- Sintilimab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 357 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance
Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)
This is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating docetaxel plus plinabulin versus docetaxel plus placebo in participants with advanced or metastatic non-squamous non-small cell…
- Trial name
- NCT07361484
- Testing
- Plinabulin, Docetaxel
- Volunteers
- 442 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
NSCLC
QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC
The goal of this clinical trial is to evaluate QL1706 plus bevacizumab with or without chemotherapy in patients with PD-L1-negative, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) previously…
- Trial name
- NCT07134413
- Testing
- QL1706 plus bevacizumab with or without chemotherapy
- Volunteers
- 77 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-squamous Non-small Cell Lung Cancer
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small…
- Trial name
- NCT02264990
- Testing
- Paclitaxel, Carboplatin, Cisplatin
- Where
- 140 sites in United States, Argentina and 18 more
- Volunteers
- 595 people
- Sponsor
- AbbVie
Non-Squamous Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This 3 arm study will evaluate the efficacy and safety of adding Avastin versus placebo to a standard chemotherapeutic regimen in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) who have not…
- Trial name
- NCT00806923
- Testing
- Cisplatin, Gemcitabine, bevacizumab [Avastin]
- Where
- 154 sites in Argentina, Australia and 18 more
- Volunteers
- 1,044 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00028938
- Testing
- epoetin alfa, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Non-Squamous Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
This single arm study will assess the safety and efficacy of Avastin combined with platinum-containing chemotherapy regimens in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT00451906
- Testing
- Platinum-based chemotherapy, Bevacizumab [Avastin]
- Where
- 369 sites in Argentina, Australia and 38 more
- Volunteers
- 2,252 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
The objective of this study is to test a clinical benefit of the addition of CP 751,871 to erlotinib therapy in patients with advanced NSCLC of non adenocarcinoma histology. The primary endpoint is Overall Survival (OS).
- Conditions
- Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Adenosquamous Cell
- Trial name
- NSCLC (NCT00673049)
- Testing
- CP 751,871 (Figitumumab), Erlotinib
- Where
- 175 sites in United States, Belgium and 25 more
- Volunteers
- 583 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC)
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety…
- Conditions
- Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma
- Trial name
- LB-LR1109 (NCT06332755)
- Testing
- Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- LG Chem
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
Primary Objective: Safety run-in part: to assess the tolerability and to determine the recommended doses of tusamitamab ravtansine in combination with pembrolizumab and tusamitamab ravtansine in combination with pembrolizumab and…
- Trial name
- CARMEN-LC05 (NCT04524689)
- Testing
- SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin
- Where
- 22 sites in United States, Brazil and 6 more
- Volunteers
- 57 people
- Sponsor
- Sanofi
Advanced Non-Small Cell Lung Cancer
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
This Phase Ib/III study evaluates the efficacy and safety of IBI351 in combination with chemotherapy in advanced non-squamous NSCLC with KRAS G12C mutation.
- Trial name
- NCT05504278
- Testing
- IBI351, Cetuximab, pemetrexed
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Lung Cancer
Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00309998
- Testing
- bevacizumab, vinorelbine tartrate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Rochester
Lung Cancer
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00234052
- Testing
- bevacizumab, carboplatin, pemetrexed
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Northwestern University